Study participants who saw the lower-priced TV ads for a medication said they were likely to research the drug, ask about it, or take it when the price was $50 per month, but less so when it was more expensive. (Photo: Shutterstock)
Not surprisingly, cost matters when it comes to drugs being advertised to consumers, a new study finds. The report, published in the Journal of the American Medical Association's (JAMA) Internal Medicine, examined how consumers would react to direct-to-consumer (DTC) television ads by drug manufacturers, if prices for the drugs were included.
“In the 'American Patients First' blueprint released in May 2018, the Trump administration proposed including the drug price in any direct-to-consumer pharmaceutical advertising as an approach to lower prescription drug prices,” the report's authors wrote. “In October 2018, the Centers for Medicare and Medicaid Services proposed requiring that television [DTC pharmaceutical advertising] disclose drug prices. We conducted a behavioral experiment to understand how consumers are likely to respond to price disclosure.”
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
